It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
In the long term, 137Cs is probably the most biologically important agent released in many accidental (or malicious) radiation disasters. It can enter the food chain, and be consumed, or, if present in the environment (e.g. from fallout), can provide external irradiation over prolonged times. In either case, due to the high penetration of the energetic γ rays emitted by 137Cs, the individual will be exposed to a low dose rate, uniform, whole body, irradiation. The VADER (VAriable Dose-rate External 137Cs irradiatoR) allows modeling these exposures, bypassing many of the problems inherent in internal emitter studies. Making use of discarded 137Cs brachytherapy seeds, the VADER can provide varying low dose rate irradiations at dose rates of 0.1 to 1.2 Gy/day. The VADER includes a mouse “hotel”, designed to allow long term simultaneous residency of up to 15 mice. Two source platters containing ~ 250 mCi each of 137Cs brachytherapy seeds are mounted above and below the “hotel” and can be moved under computer control to provide constant low dose rate or a varying dose rate mimicking 137Cs biokinetics in mouse or man. We present the VADER design and characterization of its performance over 18 months of use.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Columbia University, Radiological Research Accelerator Facility, Irvington, USA (GRID:grid.21729.3f) (ISNI:0000000419368729); Columbia University, Center for Radiological Research, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
2 Columbia University, Radiological Research Accelerator Facility, Irvington, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
3 Columbia University, Center for Radiological Research, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
4 Columbia University, David A. Gardner PET Imaging Research Center, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
5 Columbia University, Department of Radiation Oncology, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
6 Columbia University, Environmental Health and Safety, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
7 Georgetown University, Department of Oncology, Lombardi Comprehensive Cancer Center, Washington DC, USA (GRID:grid.213910.8) (ISNI:0000 0001 1955 1644); Georgetown University, Department of Biochemistry and Molecular and Cellular Biology, Washington DC, USA (GRID:grid.213910.8) (ISNI:0000 0001 1955 1644)